title: National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool.
abstract: OBJECTIVE
  HMG-CoA reductase inhibitors (statins) are extensively used in treating hypercholesterolemia. The statins available in Malaysia include atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and fluvastatin. Over the years, they have accumulated in the National Drug Formulary; hence, the need for review. Effective selection of the best drugs to remain in the formulary can become complex due to the multiple drug attributes involved, and is made worse by the limited time and resources available. The multiattribute scoring tool (MAST) systematizes the evaluation of the drug attributes to facilitate the drug selection process. In this study, a MAST framework was developed to rank the statins based on their utilities or benefits.
  
  
  METHODS
  Published literature on multicriteria decision analysis (MCDA) were studied and five sessions of expert group discussions were conducted to build the MAST framework and to review the evidence. The attributes identified and selected for analysis were efficacy (clinical efficacy, clinical endpoints), safety (drug interactions, serious side effects and documentation), drug applicability (drug strength/formulation, indications, dose frequency, side effects, food-drug interactions, and dose adjustments), and cost. The average weights assigned by the members for efficacy, safety, drug applicability and cost were 32.6%, 26.2%, 24.1%, and 17.1%, respectively. The utility values of the attributes were scored based on the published evidence or/and agreements during the group discussions. The attribute scores were added up to provide the total utility score.
  
  
  RESULTS
  Using the MAST, the six statins under review were successfully scored and ranked. Atorvastatin scored the highest total utility score (TUS) of 84.48, followed by simvastatin (83.11). Atorvastatin and simvastatin scored consistently high, even before drug costs were included. The low scores on the side effects for atorvastatin were compensated for by the higher scores on the clinical endpoints resulting in a higher TUS for atorvastatin. Fluvastatin recorded the lowest TUS.
  
  
  CONCLUSIONS
  The multiattribute scoring tool was successfully applied to organize decision variables in reviewing statins for the formulary. Based on the TUS, atorvastatin is recommended to remain in the formulary and be considered as first-line in the treatment of hypercholesterolemia.
authors.affiliation: United Nations University International Institute for Global Health (UNU-IIGH), Kuala Lumpur, Malaysia ; Pharmaceutical Services Division, Ministry of Health, Petaling Jaya, Malaysia.
authors.forename: Azuana
authors.initials: A
authors.lastname: Ramli
authors.affiliation: United Nations University International Institute for Global Health (UNU-IIGH), Kuala Lumpur, Malaysia ; International Centre for Casemix and Clinical Coding (ITCC), Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
authors.forename: Syed Mohamed
authors.initials: SM
authors.lastname: Aljunid
authors.affiliation: International Centre for Casemix and Clinical Coding (ITCC), Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
authors.forename: Saperi
authors.initials: S
authors.lastname: Sulong
authors.affiliation: Pharmaceutical Services Division, Ministry of Health, Petaling Jaya, Malaysia.
authors.forename: Faridah Aryani
authors.initials: FA
authors.lastname: Md Yusof
keywords: drug attributes; drug selection; multicriteria decision analysis; utility score